To describe the pharmaceutical use, health care resource utilisation patterns, and annual direct medical cost of epilepsy as well as determining the impact of various demographic and clinical characteristics on total costs of epilepsy in Oman. Methods: Medical and pharmacy data were collected for 6 months on all patients aged ≥13 years attending the Sultan Qaboos University Hospital. Unit pharmacy and medical costs were retrieved for each patient, and multiple linear regression was utilised to analyse the impact of various demographic and clinical characteristics on total cost. Results: A total of 486 patients were seen over the study period. Annual direct medical costs of epilepsy amounted to US$1426. In-patient care, the antiepileptic drug (AED) lamotrigine and specialist visits, respectively, were the first, second and third most significant predictors of total cost. Age was associated positively, and was the most significant predictor of total costs among demographic and clinical parameters. Conclusions: This analysis, the first economic study of epilepsy in Oman, could assist in health care allocation of scarce resources and in pharmacoeconomic analysis of AEDs. Besides in-patient admission, our findings demonstrate that the newer drugs are significant predictors of total cost, and hence any incremental benefits derived from them must be rigorously assessed for their cost-effectiveness.
INTRODUCTION
Epilepsy is a common and chronic neurologic disorder with an annual incidence of 50-100 cases per 100 000 people and an overall prevalence of between 8 and 10 per 1000 people 1 . The 1995 lifetime costs of epilepsy for annual incident and prevalent cases in the United States were estimated at $11.1 and $12.1 billion, respectively 2 . Epilepsy causes significant medical and social costs, and places an economic burden on society and individuals by causing increases in health care costs, as well as losses in employment, wages and household work.
To our knowledge, a cost analysis of epilepsy has never been conducted in Oman or the Arabian Peninsula. Studies conducted in the United States or Europe cannot be extrapolated to this region because of major variations in methodology. A study's perspective (i.e. costs involved, definition, design, and duration of study period), may all affect the overall costs 3, 4 . The inability to generalise cost data across geographic regions has recently been demonstrated in a cost comparison study of epilepsy in eight Western European countries. The study showed that the charges levied to health services payers varied by as much as a factor of 24 and the cost of antiepileptic drugs (AEDs) varied by up to 4.4 times across countries 5 . This variation occurs despite the fact that the countries share broadly similar economic and medical systems.
The Sultanate of Oman, located at the south-east part of the Arabian Peninsula, has a population of about 2.3 million. The health care system in Oman has expanded rapidly since 1970. Up until that time, there were only two hospitals in the country with health care largely provided by traditional herbal and spiritual medicine. There are now over 60 hospitals in addition to more than 170 government health care centres. In the last three decades, the health care system in Oman has developed to such an extent that the World Health Organization, in its World Health Report 2000, rated Oman's health care system as 8th among 191 member states. In addition, health care is free to all natives of the country, as well as to expatriates working for the government.
In this period of cost containment, cost estimates are becoming increasingly more valuable, and are being utilised more and more by various economic decision-makers to plan how the scarce health resources can be allocated most efficiently. The aim of this study was to quantify, based on direct observations of real and detailed medical and pharmacy data of adult epileptic patients, the annual direct medical costs of epilepsy in Sultan Qaboos University Hospital (SQUH), a tertiary referral hospital in Oman. These costs are analysed from the perspective of a governmental hospital along with the impact on cost of various demographic, clinical and pharmaceutical characteristics of epilepsy.
METHODS

Patient population
This was an observational study of all epileptic patients aged 13 and above, seen at SQUH in Oman over the 6-month period of 1 January 2000 to 30 June 2000. SQUH is located within the capital area and provides health care to at least 200 000 people. This hospital-based approach to sampling was able to capture all epileptic patients in this area because unlike the United States or Europe, all patients with chronic diseases in Oman are followed-up via a hospital-based GP or specialist (neurologist or psychiatrist). Thirteen years of age was chosen because it is the existing cut-off age for patients admitted in adult medical, surgical and intensive care units.
Epilepsy was defined as a chronic disorder characterised by recurrent and unprovoked seizures, and was confirmed by the results of EEG, CT or MRI testing. Patients were identified daily through in-and out-patient registers, and pharmacy records of prescriptions. Due to ethical concerns, and as a requirement from the Institutional Review Board, patient confidentiality was strictly maintained.
Data collection
The data collection form included fields for health care resource utilisation patterns, including in-patient, GP and specialists' visits, demographic information (age and gender), patient status (new or known), epilepsy type and aetiology, neurophysiological test (EEG), neuroradiological investigations (CT, MRI), other laboratory tests (serum AED levels, liver and kidney function tests, and haematological investigations), as well as pharmacy data. Seizure types were grouped as complex partial, simple partial, tonic-clonic, absence, myoclonic, clonic, tonic, atonic and status epilepticus in accordance with the classification system of the International League Against Epilepsy 6 . The following aetiologies were considered: idiopathic/cryptogenic, trauma, infection, tumour, drug-induced, stroke, systemic disease, metabolic/toxic and degenerative. As this study was purely observational, and in no way interfered with the management of any patient, no protocol-induced costs were considered.
Direct medical costs
Direct medical costs were collected for all epilepsyrelated health care utilisations, including in-patient admissions, GP and specialist visits, laboratory and radiological investigations, and costs of pharmaceuticals. The costs for laboratory and radiological investigations were obtained from SQUH's administrative fee schedule of July 2000.
As in-patient, GP and specialist costs (per visit) were heavily subsidised and not truly representative of actual costs, the charges for these services were obtained from a private hospital (Muscat Private Hospital), where some of the specialists share staff privileges. Drug costs were based on the year 2000 acquisition cost of drugs by the hospital. Total drug costs were then calculated using the unit prices and duration of prescriptions. In order to be able to compare outcomes to other countries, and because the Omani Rial was fixed to the US dollar, the total costs were converted to US dollars by a multiplication factor of 2.56, which was the existing exchange rate at the initiation of the study (1 January 2000).
Statistical methods
Descriptive statistics included means and relative frequencies for continuous and categorical data, respectively. Outcome variables were evaluated using parametric and nonparametric tests as appropriate. The dependent variable was the total cost. The independent variables included demographics (age, gender [with male as reference], patient status [with known patient as reference]); seizure type (with partial seizures as reference); aetiology type (with idiopathic/ cryptogenic as reference); medications (carbamazepine, sodium valproate, lamotrigine, clonazepam, phenytoin, phenobarbitone, vigabatrin, other drugs); and hospital-based variables (length of hospital stay, specialists visits, GP visits, EEG, CT scan and MRI). Medications were measured as continuous variables representing the number of times they were refilled. Hospital-based variables were represented as the number of times each were utilised.
The relationships were examined with multiple linear regression, while controlling for co-linearity. Transformations were used where necessary to normalise the dependent (cost) variable that was not normally distributed. Multiple linear regressions were carried out first on the cost of out-patients and then on the total aggregated patients (including in-and out-patients). Variables were entered into the regression models simultaneously. For all analyses, a two-tailed P value <0.05 was considered statistically significant.
A rule of thumb in multiple regression analysis 7 is that there should be at least 10-30 subjects per independent variable. With the sample size of 486, the ratio of subjects to independent variables in this study was 22 to 1 and well within the recommended threshold. Statistical analyses were performed using SPSS version 10.07 (SPSS Inc., Chicago, IL).
RESULTS
Demographic and clinical characteristics
A total of 486 epilepsy patients were seen as either in-patients or out-patients over the 6-month study period. The mean age of the patients was 28 years old (28.5 years for men, 27.7 for females) with an age range of 14-77 years. There were roughly an equal number of males (49.8%) and females. Only 2.3% of patients were aged 65 years or over, and 97.7% fell between 14 and 64 years of age. Forty-eight (∼10%) patients were newly diagnosed. A majority of patients (56.8%) suffered from generalised seizures (tonic-clonic 50.6%, absence 0.2%, myoclonic 5.8%, tonic 0.2%). Partial seizures included complex (41.8%) and simple partial (1.4%) in origin. The majority (80%) of seizures were idiopathic/cryptogenic in nature. The known causes of epilepsy included systemic disease (5.6%), trauma (5.6%), infection (3.9%), stroke (2.1%), metabolic/toxic (1.7%), brain tumour (0.6%) and degenerative (0.6%) ( Table 1) .
Health care resource use
The number of patient visits totalled 1039. This included 87 in-patient admissions (among a total of 53 patients), 594 specialist visits and 358 GP visits. In-patient service utilisation between the sexes was similar in some respects but markedly different in others. The females were not only admitted more frequently (59 vs. 28 admissions; P = 0.002), but also spent on average nearly three times as much time in the hospital (20.0 days vs. 7.4 days; P = 0.0263) than the males during the study period. The overall hospital admission rate was 8.4% (87/1039 = 0.084). The average length of hospital stay for those who were admitted was 9.0 days. Other services (GP and specialist visits, MRI, CT and EEG) were evenly utilised between the two genders. The patients had on average 1.22 and 0.66 specialist and GP visits, respectively. During the 6-month period, 19.3% of patients had an EEG while 11.3 and 3.3% of the patients had CT and MRI scans, respectively (Tables 1 and 2 ).
AED refill pattern and cost
A total of 652 AEDs were prescribed during the study period with an average of 1.34 drugs per patient. A total of 1460 AEDs were dispensed corresponding to an average of just over three prescription refills per patient per 6 months. The most common AED refill was sodium valproate (35.4%) followed by carbamazepine (30.8%) and lamotrigine (9.7%). All patients were prescribed at least one AED. Nearly 74% were on monotherapy, 19% were on two AEDs, and nearly 6% were on three or more AEDs. There were five patients on four AEDs. The projected annual cost of AEDs amounted to US$156 898 with an average of US$323 per patient per year (Table 3) .
Annual direct medical cost
The total annual direct medical cost of epilepsy for the hospital was calculated to be US$1432. The sin- gle most significant and expensive contributor to total cost was in-patient utilisation, which accounted for nearly 52% of the total cost. Pharmaceutical expenditure (22.5%) and specialist visits (13.2%) were the second and third most expensive cost elements, respectively (Table 4) .
Cost impact of various demographic and clinical parameters
Since the total cost was not normally distributed, a logarithmic computation was performed to normalise the dependent cost variable. All tolerance values exceeded 0.1; likewise, the variance inflation factor (VIF) values were also well below the threshold mark of 10. Both of these results indicated that interpretation of the regression coefficients was not affected by multi-collinearity. For out-patients, the model fit the data well (R 2 = 0.762, F = 80.727, P = 0.001). The predictor that weighed most highly on total cost was specialist visits Idio/crypto = idiopathic/cryptogenic; AED = antiepileptic drug; LOS = length of hospital stay. * P = < 0.05. ** P = < 0.01. *** P = < 0.001.
followed by the drug lamotrigine and CT utilisation. The only significant predictors of total costs among the demographic and clinical parameters were epilepsy type and aetiology. Patients with partial seizures were associated with lower total costs compared to those with generalised seizures. Additionally, those with idiopathic epilepsy in aetiology were associated with lower costs compared to those with epilepsy of known origin (Table 5 ). For both in-patients and out-patients, the data also fit the model well (R 2 = 0.729, F = 58.838, P = 0.001). As expected, the length of hospital stay had the greatest weight followed by the newer drug lamotrigine and then specialist visits. The only significant predictor of total costs among the demographic and clinical parameters when all patients were aggregated was age. The relationship was positive; as patients grew older, total costs increased.
DISCUSSION
The mean estimated annual direct medical cost of epilepsy for our cohort was US$1432 using a government hospital perspective in year 2000 dollars. In-patient admission was the most important contributor to total cost, and accounted for nearly 52% of the total cost. The second and third most important predictors of total cost were pharmaceutical use and specialist visits, which accounted for 22.5 and 13.1% of the total annual direct medical cost, respectively.
De Zelicourt et al. 8 conducted a similar 2-year longitudinal, prospective cohort study in France in 1998. The annual direct medical cost in our cohort was lower than their first year cost (US$1432 vs. US$1954). Like our cohort, their most significant contributor to total cost was in-patient care, representing 68% of the total first year costs. However, their second contributors were CT scan and MRI use. Despite the fact that our study's hospitalisation rate at 8.4% was much lower compared to theirs (65%), the average length of hospital stay in our study was much higher (9.0 days vs. 4.5 days). The higher hospitalisation rate in the De Zelicourt study 8 was not surprising as they were following only new cases of epilepsy, and thus patients had to be admitted for the medical work-up. Only around 10% of patients in our study were newly diagnosed. One possible reason for longer hospital stays in our study could be due to the nature of the health care system in Oman which is offered free to all patients with no deductibles, co-insurance or co-payments. This can undoubtedly lead to over-utilisation of health care resources as seen in the earlier days of indemnity insurance in the United States.
Halpern et al. 9 analysed the direct medical costs associated with epilepsy in the United States via a patient-based approach using the 1987 National Medical Expenditure Survey (NMES). They adjusted the survey to reflect 1995 values using the Consumer Price Index (CPI). Their annual direct medical cost (US$1490) closely mirrored ours (US$1432). Their most important contributors to total cost were the combination of hospital and physician services, AED use, and diagnostic procedures, which accounted for 51, 24 and 10% of total cost, respectively. Unlike the French study 8 , our hospitalisation rate (8.4%) was similar to the one presented by Halpern et al. 9 in the United States (10.9%).
Our cohort, like that in the study conducted by De Zelicourt et al. 8 , showed epilepsy to be evenly distributed between the sexes. Previous findings in Oman 10 and other studies in the United States 11 have shown epilepsy to be more common in males than females. The age distribution also showed remarkable differences with those published elsewhere in Europe and the USA 8, 12, 13 . A much younger cohort characterised our study, as only 2.3% of the patients were 65 years of age or older. This is most likely due to the fact that the Omani population is relatively young. According to data published by the World Health Organization 14 , only 4.1% of Oman's population is older than 60 compared to 10% for France, 16.4% for the USA and 24% for the UK 8, 12, 13 .
Based on the number of refills, sodium valproate was the most frequently prescribed AED, followed by carbamazepine and lamotrigine. Despite representing only 9.7 and 1.2% of the prescription refills, respectively, multivariate analysis ( Table 5 ) has shown that the newer drugs, lamotrigine and vigabatrin, are among the significant predictors of total cost, with lamotrigine as the second most significant contributor for both out-patients and in-patients combined. The annual AED cost per patient (US$321) was similar to that published recently (US$364) by Halpern et al. 9 The authors acknowledge a number of limitations in this study. In spite of their obvious effectiveness, there is still some debate 15, 16 surrounding the cost-effectiveness of the newer AEDs and the questions whether their high cost is offset by reductions in seizure frequency, health service use, and improvement in functioning and quality of life. Despite the fact that this study attempted to capture all direct costs of epilepsy, it was not able to attribute costs associated with the length of hospital stay itself because of the particular problem of co-morbidities associated with epilepsy. Finally, being a tertiary care medical centre, the annual per patient cost may not be generalisable to the country as a whole as the patients seen may have more complicated medical problems with various other co-morbidities.
In summary, this analysis provides the first cost data for epilepsy treatment in Oman. The results may aid not only the institution involved, but also the country as a whole in the appropriate and efficient allocation of health care resources. The results may also provide a useful basis for pharmacoeconomic evaluations of interventions, such as those of AEDs. Besides in-patient admissions, our findings demonstrate that the newer AEDs, namely lamotrigine and vigabatrin, are significant predictors of total costs, and thus any incremental benefits derived must be rigorously assessed.
